Free Republic

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research. In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and HFpEF. HFpEF occurs when the heart muscle cannot enlarge sufficiently to accommodate the blood it receives, causing pressure in the heart to become elevated. Chronic kidney disease occurs when the kidneys do not filter waste from the blood as they should, leading to a buildup of toxins. Tirzepatide...

Novel drug treatment developed for diabetes shows promising results of enhanced sleep and overall health for patients diagnosed with obesity and living with obstructive sleep apnea ================================================================== Researchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study demonstrating the potential of tirzepatide, known to manage type 2 diabetes, as the first effective drug therapy for obstructive sleep apnea (OSA), a sleep-related disorder characterized by repeated episodes of irregular breathing due to complete or partial blockage of the upper airway. The results, published in the June 21, 2024 online edition of New...

Americans may love to eat junk, but we’re nearly as passionate about doing penance, with more than half of us scarfing down dietary supplements on a regular basis. From herbal remedies to energy boosters, vitamins and weight-loss pills, supplements form a massive global industry — one that’s expected to reach $200 billion in value by 2025, according to the AMA Journal of Ethics. Trouble is, it’s a largely “Wild West” scene — and that’s by design, believe it or not. The Dietary Supplement Health and Education Act of 1994 limits the ability of the Food and Drug Administration to regulate...

An experimental drug being clinically investigated for its effects on body weight in obese and overweight people has delivered record-breaking weight loss for participants in the trial – on par with surgical options, the company behind the drug suggests. Tirzepatide, developed by American pharmaceutical company Eli Lilly and Company (Lilly), is a once-weekly injection that promotes weight loss by mimicking the effects of natural hormones called incretins. These hormones lower blood sugar after we eat, in addition to regulating metabolic processes related to digestion. In the case of tirzepatide, which is not yet available on the market pending further clinical...